Lung cancer: Biology and treatment options
- PMID: 26297204
- PMCID: PMC4663145
- DOI: 10.1016/j.bbcan.2015.08.002
Lung cancer: Biology and treatment options
Abstract
Lung cancer remains the leading cause of cancer mortality in men and women in the U.S. and worldwide. About 90% of lung cancer cases are caused by smoking and the use of tobacco products. However, other factors such as radon gas, asbestos, air pollution exposures, and chronic infections can contribute to lung carcinogenesis. In addition, multiple inherited and acquired mechanisms of susceptibility to lung cancer have been proposed. Lung cancer is divided into two broad histologic classes, which grow and spread differently: small-cell lung carcinomas (SCLCs) and non-small cell lung carcinomas (NSCLCs). Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, and targeted therapy. Therapeutic-modalities recommendations depend on several factors, including the type and stage of cancer. Despite the improvements in diagnosis and therapy made during the past 25 years, the prognosis for patients with lung cancer is still unsatisfactory. The responses to current standard therapies are poor except for the most localized cancers. However, a better understanding of the biology pertinent to these challenging malignancies, might lead to the development of more efficacious and perhaps more specific drugs. The purpose of this review is to summarize the recent developments in lung cancer biology and its therapeutic strategies, and discuss the latest treatment advances including therapies currently under clinical investigation.
Keywords: Immunotherapies; Lung cancer; Mesothelioma; Non-Small Cell Lung; Small-cell lung carcinomas; Surgery; Targeted therapies; Therapies; Treatments.
Copyright © 2015 Elsevier B.V. All rights reserved.
Figures

References
-
- American-Cancer-Society. Cancer facts & figures 2014. Atlanta: American Cancer Society. 2014
-
- Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: Relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31(8):992–1001. - PubMed
-
- Rubin P, Hansen JT. Tnm staging atlas with oncoanatomy. Lippincott Williams and Wilkins; 2012.
-
- Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, Payne D, Kostashuk EC, Evans WK, Dixon P, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The national cancer institute of canada clinical trials group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993;11(2):336–344. - PubMed
-
- Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, Jett J, Kennedy C, Rami-Porta R, Rusch VW, Goldstraw P. The iaslc lung cancer staging project: Proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the tnm classification for lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008;3(11):1213–1223. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous